Eshan Patel, MD
Hematology & Oncology · Somerville, NJNPI 1770821498
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $322,243 of the $420,205 with a category attached, or 76.7%. 31 manufacturers reported payments, led by Johnson & Johnson at 42.1% of the total. 2025 is the largest year on record at $231,094, more than ten times the $171 reported in 2019. Among hematology & oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $661.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$177K
- AstraZeneca$117K
- Novocure Inc.$111K
- Pfizer$5K
- Janssen Scientific Affairs, LLC$3K
- Astellas Pharma US Inc$3K
- plus $3K from 25 others
Across 4 payments — averaging $3350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$13K
What the payments were for
- Consulting fees$35,3388%
- Speaking & faculty fees$322,24377%
- Travel & lodging$47,97811%
- Food & beverage$14,4883%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 255 | $177,028 |
| AstraZeneca | 142 | $117,417 |
| Novocure Inc. | 115 | $111,395 |
| Pfizer | 9 | $4,647 |
| Janssen Scientific Affairs, LLC | 3 | $3,248 |
| Astellas Pharma US Inc | 8 | $3,231 |
| Exelixis Inc. | 1 | $1,470 |
| Novartis | 16 | $256 |
| E.r. Squibb & Sons, L.L.C. | 10 | $185 |
| Gilead(2 entities) | 11 | $175 |
| Daiichi Sankyo Inc. | 11 | $170 |
| Seagen Inc. | 4 | $120 |
| Bristol Myers Squibb | 7 | $106 |
| Merck | 6 | $104 |
| Lilly USA, LLC | 6 | $103 |
| Myriad Genetic Laboratories, Inc. | 4 | $63 |
| Epizyme, Inc. | 2 | $59 |
| Bayer | 3 | $54 |
| Incyte Corporation | 3 | $53 |
| Array Biopharma Inc | 2 | $42 |
| Eisai Inc. | 3 | $42 |
| Amgen | 2 | $38 |
| Sanofi | 2 | $30 |
| Beigene USA, Inc. | 2 | $29 |
| Myovant Sciences Inc. | 2 | $29 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Dova Pharmaceuticals | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
| TG Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$420,205 in reported general payments places this provider in the 95th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 52 | $793,201 |
| CalquenceAcalabrutinib Maleate | 26 | $373,547 |
| XtandiEnzalutamide | 21 | $294,122 |
| RevlimidLenalidomide | 15 | $197,767 |
| IbrancePalbociclib | 11 | $168,986 |
| EliquisApixaban | 94 | $62,061 |
| OrgovyxRelugolix | 11 | $27,172 |
| XareltoRivaroxaban | 14 | $8,003 |
| Fentanyl | 13 | $1,547 |
| Dexamethasone | 92 | $1,406 |
| Imatinib Mesylate | 13 | $1,272 |
| Prochlorperazine Maleate | 100 | $1,046 |
| Ondansetron Hcl | 97 | $778 |
| Letrozole | 55 | $581 |
| Acyclovir | 17 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $117,417 | $1,166,74878 claims |
| Astellas Pharma US IncXtandi | $3,231 | $294,12221 claims |
| PfizerIbrance, Eliquis | $4,647 | $231,048105 claims |
| Bristol Myers SquibbRevlimid | $106 | $197,76715 claims |
| Johnson & JohnsonXarelto | $177,028 | $8,00314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Somerville
- Kathleen ToomeySomerville$16K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.